2017 Buyer’s Guide

This buyer’s guide offers a searchable, comprehensive listing of the FDA-approved interventional devices available in the United States.

Philips Completes Acquisition of Spectranetics

 

August 10, 2017—Royal Philips announced that it has completed the acquisition of Spectranetics Corporation. Philips, which is based in Amsterdam, The Netherlands, and Spectranetics, headquartered in Colorado Springs, Colorado, announced a definitive merger agreement on June 28.

As of August 9, Spectranetics’ common stock ceased trading and the company's financial results will be consolidated as part of Philips’ Image-Guided Therapy business group. As a result of the merger, all remaining Spectranetics shares were converted into the right to receive $38.50 per share in cash. Spectranetics, which has more than 900 employees, projects 2017 sales to be approximately $300 million.

Spectranetics' device portfolio includes a range of catheters to treat coronary and peripheral artery disease and for the removal of implanted pacemakers and implantable cardioverter defibrillator leads.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.